Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL496495 | 0.98 | CYP1A2 (0.30) | CYP1A2CYP2D6 | |
| SCHEMBL21815441 | 0.80 | CYP1A2 (0.31) | CYP1A2CYP2D6 | |
| SCHEMBL531924 | 0.78 | — | — | |
| Hydrochloric Acid SCHEMBL28375754 | 0.76 | CYP1A2 (0.34) | CYP1A2CYP2D6 | |
| SCHEMBL19915260 | 0.75 | CYP1A2 (0.31) | CYP1A2CYP2D6 | |
| SCHEMBL4429221 | 0.75 | — | — | |
| SCHEMBL8159853 | 0.73 | CYP1A2 (0.30) | CYP1A2CYP2D6 | |
| SCHEMBL1070324 | 0.72 | CYP1A2 (0.32) | CYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL2289852 | 0.71 | — | — | |
| SCHEMBL28308321 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8257981-B2 | Lanthanide chelates and use thereof in bioanalysis | SENSIENT IMAGING TECHNOLOGIES GMBH (DE) | 2012-09-04 | — | — | US | claimed |
| US-20110136242-A1 | Lanthanide Chelates and Use Thereof in Bioanalysis | SENSIENT IMAGING TECHNOLOGIES GMBH (DE) | 2011-06-09 | — | — | US | claimed |
| EP-1732935-B1 | LANTHANIDE CHELATES AND USE THEREOF IN BIOANALYSIS | SENSIENT IMAGING TECHNOLOGIES (DE) | 2007-12-12 | — | — | EP | claimed |
| US-6420556-B1 | MULTISTAGE REACTION FOR HYPOTENSIVE AGENTS OR CARDIOTONIC AGENTS | THE PROCTER & GAMBLE COMPANY | 2002-07-16 | — | — | US | claimed |
| WO-2000035860-A2 | ACYL ISOTHIOCYANATE RESINS AND THEIR USE IN SOLID-SUPPORTED SYNTHESIS OF GUANIDINES | THE PROCTER & GAMBLE COMPANY (US) | 2000-06-22 | — | — | WO | claimed |
| EP-0373956-B1 | Nucleotide probes | ORTHO DIAGNOSTIC SYSTEMS INC (US) | 1995-07-26 | — | — | EP | claimed |
| US-5254681-A | Process for preparing monobactames and their intermediate product | CONSIGLIO NAZIONALE DELLE RICERCHE (IT) | 1993-10-19 | — | — | US | claimed |
| EP-0411541-A2 | Process for preparing monobactames and their intermediate product | CONSIGLIO NAZIONALE DELLE RICERCHE (IT) | 1991-02-06 | — | — | EP | claimed |
| EP-3362089-B1 | IMMUNOGENIC COMPOSITIONS AGAINST S. AUREUS | SANOFI PASTEUR (FR) | 2023-12-06 | — | — | EP | disclosed |
| CN-109790202-B | Cyclic peptide, affinity chromatography carrier, labeled antibody, antibody drug complex and pharmaceutical preparation | 富士胶片株式会社 | 2022-09-13 | — | — | CN | disclosed |
| CN-108367062-B | Immunogenic compositions against staphylococcus aureus | 赛诺菲巴斯德有限公司 | 2022-05-06 | — | — | CN | disclosed |
| US-10772946-B2 | Immunogenic compositions against S. aureus | SANOFI PASTEUR (FR) | 2020-09-15 | — | — | US | disclosed |
| US-10359428-B2 | Tumor marker, monoclonal antibodies and methods of use thereof | EXTERNAUTICS S.P.A. (IT) | 2019-07-23 | — | — | US | disclosed |
| US-20180280491-A1 | IMMUNOGENIC COMPOSITIONS AGAINST S. AUREUS | SANOFI PASTEUR (FR) | 2018-10-04 | — | — | US | disclosed |
| WO-1994028940-A1 | BLOOD POOL IMAGING COMPOSITION AND METHOD OF ITS USE | THE GENERAL HOSPITAL CORPORATION (US) | 1994-12-22 | — | — | WO | disclosed |
| WO-1994005203-A1 | BIOCOMPATIBLE POLYMERS CONTAINING DIAGNOSTIC OR THERAPEUTIC MOIETIES | THE GENERAL HOSPITAL CORPORATION (US) | 1994-03-17 | — | — | WO | disclosed |
| US-5254681-A | Process for preparing monobactames and their intermediate product | CONSIGLIO NAZIONALE DELLE RICERCHE (IT) | 1993-10-19 | — | — | US | disclosed |
| EP-0563475-A1 | Cell binding agent conjugates of derivatives of CC-1065 | IMMUNOGEN INC (US) | 1993-10-06 | — | — | EP | disclosed |
| US-5180816-A | One vial method for labeling protein/linker conjugates with technetium-99M | CENTOCOR (US) | 1993-01-19 | — | — | US | disclosed |
| EP-0411541-A2 | Process for preparing monobactames and their intermediate product | CONSIGLIO NAZIONALE DELLE RICERCHE (IT) | 1991-02-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136242-A1 | Lanthanide Chelates and Use Thereof in Bioanalysis | LANCL2, LANCL1, SSB | CYP1A2 4281/4885CYP2D6 3655/4885 |
| US-20180280491-A1 | IMMUNOGENIC COMPOSITIONS AGAINST S. AUREUS | CD4, CSGALNACT1, B3GNT2 | CYP1A2 4862/4885CYP2D6 4500/4885 |
| US-10772946-B2 | Immunogenic compositions against S. aureus | CD4, CSGALNACT1, B3GNT2 | CYP1A2 4862/4885CYP2D6 4500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.